Conor Stewart
Research expert covering health & pharmaceuticals in the UK & Europe
Get in touch with us nowSales of Johnson & Johnson's medtech segment by franchise 2021-2023
Published by
Johnson & Johnson’s medtech (medical devices and diagnostics) segment earned about 10 billion U.S. dollars through its surgery franchise specifically, in 2023. Orthopedics was the second-largest franchise, generating roughly nine billion U.S. dollars that year.
In 2023, some 27.4 billion U.S. dollars were generated through the medtech division. That was roughly 36 percent of the company’s total global revenue. Over the years, the multinational company with its various segments generated more than half of its revenues in the United States, making it the company’s main market. In 2023, around 20.4 billion U.S. dollars were generated in Europe, the company’s second most yielding region.
J&J’s revenue
In 2023, Johnson & Johnson’s global revenue amounted to some 85 billion U.S. dollars, which was a decrease of around ten billion U.S. dollars compared to the previous year, caused mostly by the spin-off of its consumer health business during 2023. J&J currently has two major segments: Innovative Medicine and Medtech.In 2023, some 27.4 billion U.S. dollars were generated through the medtech division. That was roughly 36 percent of the company’s total global revenue. Over the years, the multinational company with its various segments generated more than half of its revenues in the United States, making it the company’s main market. In 2023, around 20.4 billion U.S. dollars were generated in Europe, the company’s second most yielding region.
